Archive for the ‘NueroGenetic Pharmaceuticals’ Category

NeuroGenetic Pharmaceuticals

October 16th, 2014 | Posted in 2014, NueroGenetic Pharmaceuticals

NeuroGenetic Pharmaceuticals, San Diego, received FDA approval to begin clinical trials on its NGP 555 compound to treat and prevent Alzheimer’s disease. NGP 555 is a gamma-secretase modulator demonstrating good brain penetration and targeting the gamma-secretase complex, a key enzyme in the amyloid pathway.